Paid Lupus (SLE) Clinical Trials
Lupus clinical trials actively recruiting. Access new biologics and immunomodulators. Compensation up to $4,200 for patients with systemic lupus erythematosus.
Compensation
$2,000 - $4,200
Duration
52-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-70 years
- Diagnosis of systemic lupus erythematosus (ACR or SLICC criteria)
- Active disease (SLEDAI ≥6 or BILAG A/B in at least one organ)
- Positive ANA and/or anti-dsDNA antibodies
- Stable background immunosuppressive therapy for 30+ days
- Willing to use effective contraception
Who May Not Qualify
- Severe active lupus nephritis (class III-V) requiring induction therapy
- Active CNS lupus
- Drug-induced lupus
- Severe cytopenias
- Active serious infection
Frequently Asked Questions
What lupus treatments are being studied?
+
Trials are investigating new biologics targeting B cells, interferon pathways, and various cytokines. Studies are available for general SLE, lupus nephritis, and cutaneous lupus.
How is lupus disease activity measured?
+
Disease activity is assessed using validated scoring systems (SLEDAI, BILAG) that evaluate multiple organ systems. Blood tests for complement levels and anti-dsDNA antibodies also track disease status.
Can I reduce my steroid dose during the study?
+
Many studies aim to reduce corticosteroid use as a secondary goal. Successful study treatments often allow steroid tapering, which is monitored according to study protocols.
What about studies for lupus nephritis specifically?
+
Separate trials exist for lupus nephritis, which typically require kidney biopsy confirmation and have different endpoints focused on renal function and proteinuria.